Table 3.

Other histone modification enzyme inhibitors.

Chemical class	Compound	Clinical stage	Cancer specificity	Reference/NCT number
AURKB/A inhibitor	Barasertib	Phase I and II	Acute myeloid leukemia, solid tumor	NCT03217838
AURKA/B/C inhibitor	BI-847325	Phase I	Solid tumor	NCT01324830
AURKA inhibitor	Alisertib	Phase II	Solid tumor	NCT01898078
CDKs inhibitor	Flavopiridol	Phase I and II	Myelodysplastic syndrome, acute myeloid leukemia	NCT00058240
CDK8 inhibitor	SEL120	Phase I	High-risk myelodysplastic syndrome, acute myeloid leukemia	NCT04021368
PIM kinases inhibitor	SEL24/MEN1703	Phase I and II	Acute myeloid leukemia	NCT03008187
	PIM447	Phase I	Myelofibrosis	NCT02160951
JAK2 inhibitor	Ruxolitinib	Phase II	B cell lymphoma, T cell lymphoma	NCT02912754
JAK1 inhibitor	Itacibinib	Preclinical	Leukemia, lymphoma	225
USP1 inhibitor	ML323	Preclinical	Solid tumor, leukemia	226
USP2 inhibitor	ML364	Preclinical	Colorectal cancer, mantle cell lymphoma	227
USP14/UCHL5 inhibitor	b-AP15	Preclinical	Acute myeloid leukemia, multiple myeloma	228
USP7 inhibitor	P5091	Preclinical	Multiple myeloma	229

Abbreviation: CDKs, cyclin-dependent kinases.